Melinta Therapeutics is looking forward to federal approval of its first antibiotic for treating bacterial infections, paving the way for new remedies aimed at defeating deadly drug-resistant bacteria.

When Baxdela is approved by the FDA, Melinta could begin marketing and selling the antibiotic, which is targeted at serious skin infections, including the nasty MRSA (methicillin-resistant Staphylococcus aureus).